Amazfit Partners With Female Elite Trail Runners Ruth Croft and Rosa Lara Feliu to Drive Innovation in Sports Watches
13.8.2025 15:00:00 CEST | Business Wire | Press Release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced a landmark partnership with Ruth Croft, one of the most accomplished trail and ultra runners in the world. The brand also welcomes Rosa Lara Feliu, a fast-rising Spanish mountain runner, to its growing global performance team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813966185/en/
Amazfit Partners with female Elite Trail Runners Ruth Croft and Rosa Lara Feliu to Drive Innovation in Sports Watches
Croft, born and raised in New Zealand, has spent more than a decade at the pinnacle of the sport. Her career includes prestigious wins at the Golden Trail World Series, Mont Blanc Marathon, OCC by UTMB, and Les Templiers, as well as top finishes at the sport’s most competitive ultras. Since stepping up to the ultra distance in 2020, she has claimed victories at Western States Endurance Run 100 miles, Tarawera 100K, and CCC by UTMB, and finished 2nd in her UTMB Mont-Blanc debut in 2024.
Beyond a Sponsorship: Athlete-Driven Innovation
This collaboration goes beyond a traditional sponsorship. With over five years of experience working closely with another leading sports watch brand, Croft brings a unique blend of athlete insight, market expertise, and product development experience to Amazfit.
Croft will contribute in the creation of new products and the refinement of existing ones. Drawing on her deep understanding of performance demands and her meticulous approach to training and racing, she will work closely with Amazfit’s R&D teams to help deliver the most advanced, athlete-focused sports watches on the market.
“I’m equally excited about representing Amazfit on the global stage and getting hands-on with the product development process,” said Ruth Croft. “I’ve spent years understanding what athletes truly need from their sports watches, and I look forward to bringing that knowledge to help Amazfit establish itself as the reference point for innovation and quality in the category.”
“Ruth is more than an elite athlete, she’s a partner in shaping the future of our products,” said Scott Shepley, Head of Global Marketing at Amazfit. “Her combination of world-class performance and deep product knowledge aligns perfectly with our vision to build wearables that perform at the highest level while staying true to the needs of the athletes who wear them.”
Rosa Lara Feliu: A Rising European Force
Joining Croft is Rosa Lara Feliu, a rising star in European mountain running known for her calm, tactical race style and strong connection to the grassroots trail community in Spain. Her breakout performances include top finishes at Marathon du Mont-Blanc and Zegama-Aizkorri, and a victory at Val d’Aran by UTMB. Rosa represents the next generation of elite female athletes blending competitive ambition with authenticity, making her an ideal fit for Amazfit’s growing presence in Southern Europe.
Performance Backed by Technology
Both athletes will integrate Amazfit’s T-Rex 3, the brand’s most rugged GPS adventure watch, into their training and race preparation, along with the lightweight, high-resilience Helio Strap. Built for endurance in extreme environments, the T-Rex 3 delivers advanced tracking for vertical gain, heart rate, recovery, and real-time pacing, critical for navigating technical courses and managing fatigue over long distances.
Building a Global Trail Community
With Croft’s unmatched global credibility and Rosa’s fast-rising influence in Europe, Amazfit continues to strengthen its role as a trusted partner to the global endurance community. The brand’s growing investment in performance sport includes partnerships with HYROX, Escape from Alcatraz Triathlon, and Bentonville Bike Fest — all part of a long-term strategy to create products and programs built for athletes, by athletes.
About Amazfit
Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.
Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, “Discover Amazing,” encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health’s proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.
Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813966185/en/
Contacts
Press Contact:
Mary Woodbury
mary.woodbury@zepp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom